Organization
Biogen, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Biogen, Inc.
... years and a move that expands its already large footprint in Massachusetts. Biogen Inc., the largest Massachusetts-based drug maker, spun off Bioverativ as a separate ...
... Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and ...
... shell out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year. It's Sanofi's biggest deal since it bought Genzyme back ...
... which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share, according to people familiar with the ...
... General Electric, Waters Corp., State Street Corp., Teradyne Inc., Raytheon Co., and Biogen Inc. are expected to release their earnings reports for the fiscal quarter ...
... Jo Viney, who used to head drug discovery and immunology research at Biogen, became CSO. The Cambridge, Mass.-based company focuses on inflammatory and autoimmune diseases. ...
... Ardsley, New York-based drugmaker has attracted takeout interest from both Big Biotech Biogen and Belgium’s UCB, Bloomberg said. That interest fulfills a prophecy from Scopia ...
... Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and ...
... (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first approval for an SMA drug. The ...
... smarter drugs. An experimental drug called aducanumab, from the Massachusetts-based biotech company Biogen, is being tested in late stage trials, after showing success in reducing ...
... biosimilar product, citing such parties' infringement of three use patents owned by Biogen Inc., as the ground. Chugai has also filed an application for assisting ...
... Immunotherapeutics, among others. In addition, Adimab expanded its collaborations with Novartis, Sanofi, Biogen, Kite, Mersana, Surface Oncology, and several others. "Magenta Therapeutics is developing first-in-class ...
... CAMBRIDGE - Biogen Inc. (NASDAQ: BIIB) today announced it will report fourth quarter and year-end 2017 ...
... Leerink analyst Geoffrey Porges wrote that of companies in his team's coverage, Biogen, AbbVie and Regeneron are set to gain the most from the tax ...
... Kress, M.D., became president and CEO. After spending only six months as Biogen’s EVP and head of global therapeutic operations, Jean-Paul Kress, M.D., has jumped ...
... Boston, San Diego, and the United Kingdom, a foundation affiliated with Cambridge-based Biogen Inc. is donating $10 million over four years to support science, technology, ...
... Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial ...
... a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson's disease. Biogen, a leading CNS drugmaker is using Fitbit, a smart wearable tracker, to ...
... other specialty pharmas weren't the only drug companies to raise prices Monday. Biogen also boosted the stickers on some of its key multiple sclerosis drugs, ...
... Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, 'Biogen') announced ...
... between the Forward 11/576,871 patent application (the ''871 application') and an issued Biogen patent. The reply brief will become publicly available via the Federal Circuit ...
... problems" across the life sciences, energy and finance industries, including DowDuPont and Biogen. Accenture said its investment will help the company expand its ongoing work ...
... 206 28 Eli Lilly 30 69 91 688 519 60 356 29 Biogen 50 115 97 367 155 82 563 30 Teradata 100 58 145 ...
... Biogen's stock, which hit a high price of $480.18 a share in March, ...
Want to see the full history on Biogen, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial